Lung Cancer Trial, Recruiting NCT07003490 Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT07003490
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC) — specifically adenocarcinoma, squamous cell carcinoma, or large cell carcinoma — confirmed by a tissue biopsy or pathology test.
  • A special type of scan called a PET-CT has shown that your lung cancer has spread to lymph nodes on the opposite side of your chest from the main tumour (known as N3 stage).
  • You are between 18 and 75 years old.
  • Your heart and lungs are working well enough to safely undergo surgery, including having a heart pumping function (LVEF) of at least 45% and a breathing test result (FEV1) of at least 50% of the expected value for someone your age and size.
  • Doctors have reviewed your scans and determined that your tumour can be surgically removed, along with lymph nodes on both sides of your chest.
  • Scans of your whole body show no signs that the cancer has spread to other parts of the body (no distant metastasis).
  • You are generally in good physical health and able to carry out your normal daily activities independently (this is measured by a scoring system called ECOG, with a score of 0 or 1).
  • You and your family are willing to sign a consent form after being fully informed about the study, including its purpose, risks, and potential benefits.

Who may not be able to join:

  • Your tumour cannot be fully removed by surgery, for example because it has grown into major blood vessels, the spine, or the heart.
  • You have serious heart or lung conditions, such as heart failure, a previous heart attack, irregular heartbeat, severe asthma, or other uncontrolled long-term illnesses that make surgery unsafe.
  • Your scans show that the cancer has already spread to other organs, such as the liver, bones, or brain.
  • You have a known severe allergy to anaesthetic drugs, or your heart or lung health makes anaesthesia too risky.
  • You are currently pregnant or breastfeeding.
  • You have a psychiatric condition or are otherwise unable to fully understand and agree to the study's consent process independently.
  • You are unable to attend follow-up appointments after surgery, for example due to living too far from the hospital or other practical barriers.
  • You have another type of cancer in addition to lung cancer, particularly one with a high risk of coming back.
  • You have a known immune system disorder or severe immunodeficiency, including HIV, or you have had an organ transplant.
  • You are an older adult with multiple chronic health problems or declining physical function that makes surgery or anaesthesia too risky (confirm with trial site).
  • You have severe liver disease (such as cirrhosis) or kidney failure that could prevent you from safely having surgery or recovering from it.
  • You currently have an active infection, such as pneumonia, tuberculosis, or bacterial infection being treated with antibiotics.
  • You have diabetes with poorly controlled blood sugar or serious diabetes-related complications, such as problems with your feet or eyesight.
  • You are currently taking part in another clinical trial that could interfere with this study's treatments.
  • You are significantly malnourished or have experienced serious unintended weight loss that could affect your recovery from surgery.
  • You have a serious blood disorder, such as very low red blood cell counts (anaemia) or low platelet counts, which could cause problems with bleeding during or after surgery.
  • You are dependent on a ventilator or have had a tracheostomy (a surgical opening in the throat for breathing) due to severe long-term breathing failure.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Registry
ClinicalTrials.gov
Start date
1 January 2025
Est. completion
1 May 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Evaluation of the Efficacy of Primary Tumor Resection Combined with Bilateral Lymph Node Dissection in Non-Small Cell Lung Cancer Patients with Contralateral Thoracic Lymph Node Metastasis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov